Synthetic approaches to the 2013 new drugs

被引：66
作者：
Ding, Hong X. [1 ]
Leverett, Carolyn A. [4 ]
Kyne, Robert E., Jr. [4 ]
Liu, Kevin K. -C. [2 ]
Fink, Sarah J. [3 ]
Flick, Andrew C. [4 ]
O'Donnell, Christopher J. [4 ]
机构：
[1] Pharmacodia Beijing Co Ltd, Beijing 100085, Peoples R China
[2] Lilly China Res & Dev Ctr, Shanghai 201203, Peoples R China
[3] BioDuro Co Ltd, Shanghai 200131, Peoples R China
[4] Pfizer Worldwide Res & Dev, Groton Labs, Groton, CT 06340 USA
来源：
BIOORGANIC & MEDICINAL CHEMISTRY | 2015年 / 23卷 / 09期
关键词：
Synthesis; New drug molecules; New chemical entities; Medicine; Therapeutic agents; ADENOSINE RECEPTOR ANTAGONISTS; PALLADIUM-CATALYZED SYNTHESIS; PARKINSONS-DISEASE; DOUBLE-BLIND; ENANTIOSELECTIVE SYNTHESIS; ASYMMETRIC-SYNTHESIS; SELECTIVE INHIBITOR; DISCOVERY; 1ST; MACITENTAN;
D O I：
10.1016/j.bmc.2015.02.056
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
New drugs introduced to the market every year represent privileged structures for particular biological targets. These new chemical entities (NCEs) provide insight into molecular recognition and also serve as leads for designing future new drugs. This annual review covers the synthesis of twenty-four NCEs that were approved for the first time in 2013 and two 2012 drugs which were not covered during the previous edition of this review. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码：1895 / 1922
页数：28
相关论文
共 223 条
[1]   Discovery of a Highly Potent and Selective MEK Inhibitor: GSK1120212 (JTP-74057 DMSO Solvate) [J].
Abe, Hiroyuki ;
Kikuchi, Shinichi ;
Hayakawa, Kazuhide ;
Iida, Tetsuya ;
Nagahashi, Noboru ;
Maeda, Katsuya ;
Sakamoto, Johei ;
Matsumoto, Noriaki ;
Miura, Tomoya ;
Matsumura, Koji ;
Seki, Noriyoshi ;
Inaba, Takashi ;
Kawasaki, Hisashi ;
Yamaguchi, Takayuki ;
Kakefuda, Reina ;
Nanayama, Toyomichi ;
Kurachi, Hironori ;
Hori, Yoshikazu ;
Yoshida, Takayuki ;
Kakegawa, Junya ;
Watanabe, Yoshihiro ;
Gilmartin, Aidan G. ;
Richter, Mark C. ;
Moss, Katherine G. ;
Laquerre, Sylvie G. .
ACS MEDICINAL CHEMISTRY LETTERS, 2011, 2 (04) :320-324
[2]  
Adams JL, 2009, WO Pat, Patent No. [WO2009137391A2, 2009137391]
[3]   Enantioselective synthesis of levomilnacipran [J].
Alliot, Julien ;
Gravel, Edmond ;
Pillon, Florence ;
Buisson, David-Alexandre ;
Nicolas, Marc ;
Doris, Eric .
CHEMICAL COMMUNICATIONS, 2012, 48 (65) :8111-8113
[4]  
Alonso-alija C., 2007, US Patent, Patent No. [7173037B2, 7173037]
[5]   Relationships Among Pain, Depressed Mood, and Global Status in Fibromyalgia Patients: Post Hoc Analyses of a Randomized, Placebo-Controlled Trial of Milnacipran [J].
Arnold, Lesley M. ;
Palmer, Robert H. ;
Gendreau, R. Michael ;
Chen, Wei .
PSYCHOSOMATICS, 2012, 53 (04) :371-379
[6]   Levomilnacipran (F2695), a norepinephrine-preferring SNRI: Profile in vitro and in models of depression and anxiety [J].
Auclair, A. L. ;
Martel, J. C. ;
Assie, M. B. ;
Bardin, L. ;
Heusler, P. ;
Cussac, D. ;
Marien, M. ;
Newman-Tancredi, A. ;
O'Connor, J. A. ;
Depoortere, R. .
NEUROPHARMACOLOGY, 2013, 70 :338-347
[7]  
Axt S. D., 2008, Preparation of Nucleosides Ribofuranosyl Pyrimidines, Patent No. [2008045419A1, 2008045419, WO2008045419A1]
[8]   Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder [J].
Bang-Andersen, Benny ;
Ruhland, Thomas ;
Jorgensen, Morten ;
Smith, Garrick ;
Frederiksen, Kristen ;
Jensen, Klaus Gjervig ;
Zhong, Huailing ;
Nielsen, Soren Moller ;
Hogg, Sandra ;
Mork, Arne ;
Stensbol, Tine Bryan .
JOURNAL OF MEDICINAL CHEMISTRY, 2011, 54 (09) :3206-3221
[9]   Fibromyalgia Syndrome: Etiology, Pathogenesis, Diagnosis, and Treatment [J].
Bellato, Enrico ;
Marini, Eleonora ;
Castoldi, Filippo ;
Barbasetti, Nicola ;
Mattei, Lorenzo ;
Bonasia, Davide Edoardo ;
Blonna, Davide .
PAIN RESEARCH AND TREATMENT, 2012, 2012
[10]  
Biller S. A., 1998, US Patent, Patent No. 5739135
12345678910